Equillium has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering. No pricing details were given in the filing, but the offering is valued up to $86.25 million. The company intends to list its shares on the Nasdaq under the symbol EQ.
The underwriters for the offering are Jefferies, Leerink and Stifel.
This is a biotechnology company leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need.
Its initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas, including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders.
[nativounit]
As such, the firm believes EQ001 may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.
The company intends to use the net proceeds from this offering for a couple things:
- Approximately $50.0 million to fund research and development of EQ001; and
- The remainder for working capital and other general corporate purposes, including the additional costs associated with being a public company.
[recirclink id=495642]
[wallst_email_signup]
Top Gaining Stocks
Top Losing Stocks